Compare DVN & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DVN | GEHC |
|---|---|---|
| Founded | 1971 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Computer Software: Prepackaged Software |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2B | 32.1B |
| IPO Year | 1999 | 2022 |
| Metric | DVN | GEHC |
|---|---|---|
| Price | $48.36 | $70.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 13 |
| Target Price | $50.15 | ★ $88.77 |
| AVG Volume (30 Days) | ★ 11.8M | 2.8M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.00% | 0.20% |
| EPS Growth | N/A | ★ 4.84 |
| EPS | 4.17 | ★ 4.55 |
| Revenue | $17,188,000,000.00 | ★ $20,625,000,000.00 |
| Revenue This Year | $28.91 | $7.12 |
| Revenue Next Year | $8.55 | $4.45 |
| P/E Ratio | ★ $11.48 | $15.11 |
| Revenue Growth | ★ 7.83 | 4.84 |
| 52 Week Low | $29.70 | $66.95 |
| 52 Week High | $52.71 | $89.77 |
| Indicator | DVN | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 43.44 |
| Support Level | $41.83 | $69.59 |
| Resistance Level | $52.71 | $75.11 |
| Average True Range (ATR) | 1.50 | 1.70 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 89.07 | 25.91 |
Devon Energy is an oil and gas producer with acreage in several top US shale plays. While roughly two-thirds of its production comes from the Permian Basin, it also holds a meaningful presence in the Anadarko, Eagle Ford, and Bakken basins. If the merger with Coterra is successful, it will have a foothold in the gas-driven Appalachian Basin, as well. At the end of 2025, Devon reported net proved reserves of 2.4 billion barrels of oil equivalent, up from 2.2 billion in 2024. Net production averaged roughly 840,000 barrels of oil equivalent per day in 2025 at a ratio of 73% oil and natural gas liquids and 27% natural gas.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).